A cute stroke is the second leading cause of death in industrialized countries 1 and the leading medical cause of acquired adult disability. Rapid intervention after the onset of a stroke can limit neurologic damage and improve patients' recovery of functioning. 2 In most countries, only thrombolysis with the use of alteplase is currently approved for treatment, and it must be initiated within the first three hours after the onset of an acute ischemic stroke. The brief window of time and a perceived risk of bleeding, along with an absolute necessity for neuroimaging before the treatment can be initiated and the required training in the use of alteplase, have limited its application to less than 5 percent of patients with stroke, even in the United States. 3 There is a pressing need for a more widely applicable therapy.
So far, neuroprotection in patients with stroke has been unsuccessful. 4, 5 To help in the identification of potential treatments, the Stroke Therapy Academic Industry Roundtable (STAIR) group has recommended criteria that should be met before a putative neuroprotectant is evaluated in advanced clinical trials. 6 A major contributor to brain injury after stroke is tissue oxidation as a result of processes initiated by free radicals. Studies in genetically modified mice that overexpress or are deficient in antioxidant proteins indicate that the capacity for an antioxidant defense critically influences the extent of permanent brain damage after ischemia. 7 NXY-059 is a free-radical-trapping agent 8 that reduces the size of the infarct and preserves brain functioning in animal models of acute ischemic stroke and is a neuroprotectant that meets the STAIR criteria. 6, [9] [10] [11] [12] [13] [14] [15] [16] We report the results of the Stroke-Acute Ischemic NXY Treatment (SAINT I) study, the first of two efficacy trials involving patients with acute ischemic stroke, in which clinically attainable plasma concentrations of the study drug were used that have an acceptable adverse-event profile. 17, 18 Me thods
Study Design
We conducted a randomized, double-blind, placebo-controlled trial in which patients were enrolled from May 2003 through November 2004 at 158 hospitals in 24 countries. The trial was approved by local and national institutional review boards, and informed consent was obtained from the patients or from legally acceptable surrogates. The steering committee developed the trial protocol, approved the statistical plan, had full access to the data, wrote the manuscript, and was responsible for decisions with regard to publication. The academic authors vouch for the veracity and completeness of the data and the data analyses. An independent data safety monitoring board conducted safety reviews and a futility analysis.
Patients
Patients were eligible if they were conscious, were 18 or more years of age, had a clinical diagnosis of acute stroke that had commenced within the six hours before entry into the study, had limb weakness, and had a score of at least 6 on the National Institutes of Health Stroke Scale (NIHSS).
Study Intervention
Patients were randomly assigned to receive an intravenous infusion of either NXY-059 or placebo within six hours after the onset of the stroke, but each site was required to maintain an average time from onset of the stroke to treatment of no more than four hours. Randomization was performed by telephone with the use of a central interactive voice-response system that was accessed by the investigators. Patients undergoing randomization were stratified according to country, NIHSS score at baseline, side of cerebral infarct, and intention to treat with alteplase; we used a dynamic algorithm to maintain a balance of prognostic factors between the two study groups. 19 The study drug was supplied as a concentrate to be diluted to 15 mg per milliliter in 500 ml of a solution of 0.9 percent saline. The vials containing the study drug and the placebo were visually identical. Apart from 11 documented cases, investigators and assessors were unaware of the treatment assignments throughout the trial until after the database was locked; no laboratory test or adverse event was known to distinguish the active drug from the placebo. The initial infusion rate was 2270 mg (5940 μmol) per hour, reduced after 1 hour to 480 to 960 mg (1260 to 2520 μmol) (32 to 64 ml) per hour for a further 71 hours, with the aim of maintaining a target concentration of 260 μmol per liter. An estimated rate of creatinine clearance based on the serum creatinine concentration 20 guided the rate adjustment (to 44 ml per hour for an estimated rate of creatinine clearance of 51 to 80 ml per minute, and 32 ml per hour for an estimated rate of creatinine clearance of 30 to 50 ml per minute) within the first four hours; patients with an estimated rate of creatinine clearance below 30 ml per minute were withdrawn from the study treatment. In all other respects, patients received the standard of care for acute stroke.
Clinical Assessment
Patients were formally assessed at enrollment, at 24 and 72 hours after enrollment, and at 7, 30, and 90 days. The initial assessments were focused on the severity of the stroke according to scores on the NIHSS (scores range from 0 to 42, with higher scores indicating increasing severity) and were performed by observers trained and certified in the use of this scale. 21 Assessments during followup included functional measures, primarily the score on the modified Rankin scale (with a range from 0, indicating no residual symptoms, to 5, indicating bedbound, requiring constant care) and the Barthel index (with a range from 0 to 100, with 100 indicating no deficit and 0 indicating complete dependence). 22,23 Investigators were trained, tested, and certified in the use of the modified Rankin scale, according to a method involving a DVD developed specifically for this trial.
Lower in our hierarchy of tests were two additional outcome measures, the Stroke Impact Scale (SIS) and the European Quality of Life-5 Dimensions (EuroQoL EQ-5D) instrument for assessing health status and the health-related quality of life. Scores on the SIS and EuroQoL EQ-5D visual-analogue scale range from 0 to 100, with lower numbers indicating a worse quality of life. Scores on the EuroQoL EQ-5D weighted index range from −0.59 to 1.0, with negative scores associated with a quality of life that is considered worse than death.
Safety Assessments
While patients were receiving infusions, vital signs and adverse events were recorded regularly. Samples for routine laboratory tests obtained at enrollment, at 24 hours after the onset of the stroke, at a further 72 hours, and at day 7 were analyzed centrally. To assess any effect of NXY-059 on hemorrhagic transformation after the administration of alteplase, neuroimaging was repeated after 72 hours in patients receiving treatment with alteplase. Patients meeting the criteria for progressive stroke (an increase in the NIHSS score of 4 points) or a new stroke during the first week also underwent follow-up imaging. Followup scans were read centrally by a radiologist who was unaware of the treatment allocation.
Statistical Analysis
The statistical analyses were prespecified and followed the intention-to-treat principle. The primary end point was the score on the modified Rankin scale at 90 days or the last rating, analyzed across the whole distribution of scores with the use of the Cochran-Mantel-Haenszel test, with adjustment for stratification variables (NIHSS score, side of the infarct, and use of alteplase), and with the use of modified ridit scores (i.e., midrank score divided by [the number of observations + 1]), to account for ordered categories. 24 Odds ratios were calculated with the use of proportional-odds logistic regression, assuming a common odds ratio across all cut points of the modified Rankin scale, and are provided only as an estimate of the treatment effect. The odds ratios were adjusted in the same way as for the primary end point. The sample size was chosen to provide 90 percent power to detect a common odds ratio for reduction of disability at 90 days of 1.3. Deaths were included in the category of worst outcome (a modified Rankin scale score of 5).
The change from the baseline NIHSS score (termed coprimary in the study protocol) was estimated by analysis of covariance with adjustment for baseline variables (baseline scores on the NIHSS, the side of infarct, and the use of alteplase); deaths from any cause were scored as 42 (worst) on the NIHSS.
Analysis of efficacy outcomes was ordered hierarchically, and formal statistical testing was performed only if the preceding end point in the hierarchy of end points was significant, with nominal P values reported beyond that point. The primary end point (modified Rankin scale) was the first in the hierarchy of end points, and the trial was considered positive if this end point was found to be significant, irrespective of end points lower in the hierarchy. 25 Neurologic functioning was deemed to be an important supporting outcome measure of stroke recovery. However, the classification of the NIHSS as the coprimary end point in the study protocol was not intended to imply joint testing with the modified Rankin scale; instead, the intention was for the NIHSS to serve as the principal end point among the secondary end points, and thus as second in the overall hierarchy of end points.
For the safety analysis, patients were considered as treated, whereas for the efficacy analyses, they were considered as randomized. The safety end points included death, serious and nonserious adverse events, laboratory values, vital signs, and neuroimaging data -neuroimaging especially for patients receiving thrombolysis. Analyses conducted post hoc included the comparison of the rates of hemorrhagic transformation after receipt of alteplase and nonparametric approaches to the examination of the NIHSS data.
The academic authors assume full responsibility for the completeness, integrity, and interpretation of the data. The sponsor, AstraZeneca, was responsible for operational aspects of the trial, including the data collection, the data storage, and the analysis, according to the approved study plan.
R esults

Baseline Characteristics
Of 1722 patients who underwent randomization, 1705 received a study infusion; 287 died, and 1387 After randomization, 30 patients received the wrong treatment kit and 7 received treatment from more than one kit. Of these 37 patients, 21 had been assigned to receive placebo and 16 to receive NXY-059. Of the 21 patients in the placebo group, 12 received some NXY-059 and 7 of the 16 patients in the NXY-059 group received only placebo. For the efficacy analyses, data on patients were analyzed according to treatment assignment. Among the patients included in the safety analysis, there was a net shift of five patients to the NXY-059 group. For three patients in each group there was no follow-up information after the patients received the infusion, and these patients were excluded from the efficacy analyses, leaving 99.6 percent of the patients in the analyses. The per-protocol population (1525 patients; 89.4 percent of all treated patients) comprised patients who did not have major violations of the study protocol. The main reason for exclusion was that the infusion was stopped for technical or other reasons not primarily related to the stroke before at least 75 percent of the target dose was administered.
completed the 90 days of follow-up. Of the 1705 patients treated, outcome data were not available for 6; thus, 1699 patients were included in the efficacy analysis. Of these 1699 patients, 850 received NXY-059 and 849 received placebo (Fig. 1) . In the trial population, the mean age was 68.4 years, and 947 of the 1705 patients (55.5 percent) were men. The two study groups were well balanced with respect to baseline prognostic variables (Table 1 ). The mean time from the onset of stroke to treatment was 3 hours 46 minutes, and 28.7 percent of the patients received treatment with alteplase. Approximately 96 percent of the patients assigned to NXY-059 achieved an unbound, steady-state plasma concentration of NXY-059 greater than 150 μmol per liter.
Clinical Outcomes
Among patients who received NXY-059, the distribution of scores on the modified Rankin scale for the primary end point of disability at 90 days was improved, as compared with the placebo group (P = 0.038 by the Cochran-Mantel-Haenszel test) (Fig. 2) . The odds for improvement integrated across all cut points of the scale were increased by NXY-059, as compared with placebo (odds ratio, 1.20; 95 percent confidence interval, 1.01 to 1.42). The primary analysis considered the full distribution of scores on the modified Rankin scale, but the difference when we categorized the scores into 0 to 1 versus 2 to 3 versus 4 to 5, as used elsewhere, 4 was significant (P = 0.03) and two of the five possible separate dichotomizations were also significant: a further 3.7 percent of patients recovered the ability to walk (modified Rankin scale score, ≤3; P = 0.02) and a further 4.4 percent of patients were completely cured (modified Rankin scale score, 0; P = 0.003). In an analysis of the distribution of the scores in the per-protocol population, the benefit remained (Cochran-Mantel-Haenszel test, P = 0.028) (Fig. 2) . Consistent with findings at 90 days, NXY-059 improved outcomes at 7 and 30 days (odds ratio, 1.31; 95 percent confidence interval, 1.09 to 1.57; and odds ratio, 1.27; 95 percent confidence interval, 1.07 to 1.52, respectively). Among survivors, functional outcome, as measured on the modified Rankin scale and analyzed by the CochranMantel-Haenszel test, was improved (P = 0.007).
NXY-059 had no effect on the prespecified analysis of the coprimary neurologic end point: the difference between the two groups in the change from baseline was only 0.1 point in the average NIHSS score (95 percent confidence interval, −1.4 to 1.1; P = 0.86). NIHSS scores showed a skewed bimodal distribution, which may have compromised the planned parametric analysis; however, a post hoc nonparametric analysis of the scores (by the Cochran-Mantel-Haenszel test, as used for the analysis of scores according to the modified Rankin scale) was also not statistically significant (P = 0.10). In additional post hoc analyses, complete neurologic recovery (NIHSS score, 0) was more common after treatment with NXY-059 (21.9 percent of those in the NXY-059 group and 17.3 percent of those in the placebo group; odds ratio, 1.39; 95 percent confidence interval, 1.08 to 1.79; P = 0.01), but the difference between the two groups in the frequency of excellent neurologic outcomes (NIHSS score, 0 or 1) was not statistically significant (33.1 percent in the NXY-059 group vs. 30.9 percent in the placebo group; odds ratio, 1.13; 95 percent confidence interval, 0.90 to 1.41; P = 0.28). We did not intend to test scores according to the Barthel index or other secondary end points formally unless end points with higher priority were significant, but most nominal P values were greater than 0.05 (Table 2) . There was no significant interaction between the treatment effect of the investigational drug and stroke severity, treatment with alteplase, or time from the onset of stroke to treatment, indicating that the treatment benefit is present irrespective of these factors (P = 0.72, P = 0.93, and P = 0.92, respectively, for interaction). Such analyses inevitably have low power, however, especially because the distribution of times from the onset of stroke to treatment is narrow and the proportion of patients receiving alteplase was small. We explored analyses of numerous other subgroups to assess the effect of baseline prognostic factors or coexisting conditions on the treatment effect but found no evidence of nominal significance for any biologically likely factor.
Safety Analysis
Mortality was unaltered by treatment with NXY-059 (146 patients [17.0 percent] died in the NXY-059 group and 141 patients [16.6 percent] in the placebo group; P = 0.89 by the log-rank test) (Fig. 3) . Slightly fewer patients in the NXY-059 group had adverse events than in the placebo group (662 vs. 670, respectively; 295 vs. 313 patients, respectively, had serious adverse events). Fewer patients in the NXY-059 group discontinued treatment because of adverse events than in the placebo group (45 vs. 60, respectively). With few exceptions (such as hypokalemia during infusion, which occurred in 6.4 percent of patients receiving NXY-059, as compared with 4.4 percent receiving placebo), there was no imbalance between the two groups in any adverse event and no significant change in routine laboratory values (Table 3) .
In the post hoc analysis of patients treated with alteplase, hemorrhagic transformation was less common among those receiving alteplase and NXY-059 than among those receiving alteplase and placebo (P = 0.001). Symptomatic hemorrhagic transformation (an increase in the NIHSS score of at least 4 points within 36 hours plus any blood on neuroimaging after receipt of alteplase) occurred in 6 of 240 patients who received NXY-059 (2.5 percent) and 16 of 249 patients assigned to placebo (6. 
Discussion
This trial of NXY-059 for acute ischemic stroke showed a benefit in terms of the prespecified primary end point, a reduction in disability as measured by the modified Rankin score at 90 days. This benefit was seen at both ends of the scale: 4.4 percent more patients who received the study drug became asymptomatic (modified Rankin score, 0), and 3.7 percent more were able to walk without help (score, 0 to 3), as compared with those in the placebo group. The planned coprimary analysis with the use of a scoring system for neurologic functioning (NIHSS) did not show a significant benefit of NXY-059, however. There was no statistically significant interaction between the investigational drug and stroke severity, treatment with alteplase, or time from the onset of stroke to treatment, indicating that the treatment benefit is present irrespective of these factors. Two important considerations are safety and the adverse-event profile. Both survival and the incidence of serious and nonserious adverse events were similar in the two groups, as was the case in previous trials. 17, 18 The modified Rankin scale is robust and simple, easily understood by patients and laypersons, and has reasonable properties for statistical analysis. 26 This scale reflects aspects of recovery from stroke that are directly important to patients' daily activities, and the categories of the scale distinguish clinically important states. Analysis with the use of the entire distribution is both more powerful and more relevant to a neuroprotectant than is the use of dichotomization. 27 Our use of the modified Rankin scale was rigorous, requiring all those who performed the rating to be certified as competent after undergoing training with the use of a specially developed DVD program, written guidelines, and a formal, standardized rating test involving five cases.
The NIHSS was designed to score the severity of stroke at entry into stroke-treatment trials, and not as an outcome measure. Its inclusion as the principal supporting coprimary end point was influenced by European regulatory advice. 28 The change in the NIHSS score from baseline to the last rating was not improved by treatment with NXY-059; however, the planned parametric analysis was compromised by the bimodal distribution of changes in scores, partly because of the arbitrary score of 42 (worst) assigned to patients who died. In a post hoc analysis with use of an accepted alternative test, 29,30 NXY-059 was not associated with a significant increase in the number of patients who achieved an NIHSS score of no more than 1, but the odds ratio and confidence limits were consistent with the results according to the modified Rankin scale. A considerably larger study is needed to assess secondary outcome measures reliably. Several features attest to the validity of the results. Patients and investigators remained strictly unaware of the treatment assignments, and the blinding was not compromised by the occurrence or nature of adverse events. Data were missing only rarely, and missing data were handled conservatively. Prognostic factors that influence stroke outcome were well matched and showed no interaction with the treatment effect. The per-protocol analysis confirmed the result of the intention-to-treat analysis. We examined the effect of treatment at 7 and 30 days, when any dilutional effect of unrelated conditions and age would be less: a greater benefit with NXY-059 was seen at both times. There was also evidence of a biologic signal in patients treated with alteplase: the reduction in the occurrence of intracerebral hemorrhage is consistent with protec- If the result according to scores on the modified Rankin scale is confirmed, the extent of the treatment benefit would be clinically important in light of the disabling nature of stroke. According to the dichotomized approach to outcome, which is commonly used, the number needed to treat would be 22 to produce cure or 27 to restore ambulation after stroke. However, dichotomization underestimates treatment benefits in stroke, since individual cut points are relevant only to a fraction of patients. 33 We designed the trial to test for improvements in outcome across a range of potential disabilities, rather than to provide evidence of movement across an arbitrary threshold. This design enhances the power of the trial, since it uses statistical information that would otherwise be disregarded. It also reflects the theoretical effects The benefit amounts to an average improvement of 0.13 point on the modified Rankin scale per patient, which suggests that about eight patients would need to be treated to achieve improvement equal to 1 point on the scale for one patient. On the basis of evidence from experiments in animals with regard to the effect of NXY-059, a moderate benefit delivered to many patients is a more intuitive concept than a dramatic benefit delivered to a minority.
In summary, our findings provide support for a future clinical application of neuroprotection through disruption of the ischemic cascade, as has been shown in animal models. Our results were statistically significant for the primary outcome measure, but not for other outcome measures. A confirmatory study is needed to determine whether NXY-059 has a benefit in stroke. The sample size for the companion study, SAINT II, was increased in July 2005 from 1700 to 3200 to provide 80 percent power to replicate the present findings according to the modified Rankin 
